Shanghai ST-segment Elevation Myocardial Infarction Cohort

A Prospective Multicentre Cohort Study of Acute ST-segment Elevation Myocardial Infarction

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05450757

Enrollment

2000

Registered

2022-07-11

Start date

2018-09-12

Completion date

2024-09-17

Last updated

2022-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST Elevation Myocardial Infarction

Keywords

Acute Myocardial Infarction, Cardiac Remodelling, Heart Failure

Brief summary

ST-segment elevation myocardial infarction(STEMI) remains a major cause of morbidity and mortality worldwide, despite of the early reperfusion therapy, including fibrinolysis, primary percutaneous coronary intervention (PCI),and standardized medical treatment.To improve the prognosis of STEMI patients, the management in their hospitalization should be optimized, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through PCI (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as lipid-lowering therapy. This study aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Detailed description

This study is a prospective cohort study. It aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* ST elevation myocardial infarction * Coronary angiography and percutaneous coronary intervention within 12 hours of symptom onset * Capable and willing to provide informed conset and capable of completing study visits

Exclusion criteria

* Cardiovascular shock at admission * Severe physical disability * Active malignant tumors * Active autoimmune diseases

Design outcomes

Primary

Measure	Time frame	Description
MACE	0-1 year	Major adverse cardiovascular events(MACE) in one year follow-up
Left Ventricular Function	1 month, 6month and 1 year	Left ventricular end diastolic volume(LVEDV),Left ventricular end systolic volume(LVESE),Left ventricular ejection fraction(LVEF) changes within one year follow-up
Coronary angiography	1 year	The pathological changes in culprit vessels in 1 year

Other

Measure	Time frame	Description
Synchronized analysis of phonocardiogram and electrocardiogram	1 day, 1 month, 6 months, 1 year	Synchronized PCG and ECG data using a wearable cardiac monitoring patch

Countries

China

Contacts

Primary ContactShuo Feng, M.D.,Ph.D.

fengshuorv@hotmail.com+86 15921388296

Outcome results